Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN-WEV vaccine in healthy adults
NCT06899802Phase 2Active, not recruiting
- Sponsor
- Bavarian Nordic
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Viral Vector Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MVA-BN WEV in Venezuelan equine encephalitis (VEE), eastern equine encephalitis (EEE), sponsored by Bavarian Nordic. Started Mar 2025; status: active, not recruiting.
02
Drugs
MVA-BN WEV
03
Conditions
Venezuelan equine encephalitis (VEE)eastern equine encephalitis (EEE)
Beyond the preview
Go deeper on NCT06899802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899802.